FILING ANALYSIS · MONDAY, NOVEMBER 9
Foghorn Therapeutics Inc. FHTX — 8-K: Results of Operations and Financial Condition
neutral
Foghorn Therapeutics reported a strong balance sheet with $156 million in cash and a cash runway into the second half of 2029, and provided updates on its pipeline programs, including a novel oral small molecule in inflammatory bowel disease and a selective EP300 degrader for multiple myeloma, but no quantified surprises were disclosed.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →